We are live on ! Find out more
HMC

Harvard Management Company Portfolio holdings

AUM $1.82B
1-Year Est. Return 26.23%
This Fund
S&P 500
This Quarter Est. Return
+4.96%
1 Year Est. Return
+26.23%
3 Year Est. Return
+156.3%
5 Year Est. Return
+133.98%
10 Year Est. Return
+221.37%
AUM
$807M
AUM Growth
+$2.88M
Cap. Flow
+$4.91M
Cap. Flow %
0.61%
Top 10 Hldgs %
81.37%
Holding
47
New
–
Increased
2
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
GRAB icon
Grab
GRAB
+$10.7M
2
IRON icon
Disc Medicine
IRON
+$830K

Top Sells

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$5.55M
2
LAUR icon
Laureate Education
LAUR
+$1.07M

Sector Composition

Rank Sector Weight
1 Communication Services 43.32%
2 Consumer Discretionary 19.46%
3 Healthcare 17%
4 Technology 15.72%
5 Financials 1.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIGL
26
DELISTED
Vigil Neuroscience
VIGL
$3.62M 0.45%
289,460
– –
NRIX icon
27
Nurix Therapeutics
NRIX
$2.61B
$3.46M 0.43%
314,762
– –
KNTE
28
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$3.04M 0.38%
498,001
– –
FULC icon
29
Fulcrum Therapeutics
FULC
$288M
$2.99M 0.37%
410,714
– –
CFLT
30
DELISTED
Confluent
CFLT
$2.9M 0.36%
130,383
– –
PCT icon
31
PureCycle Technologies
PCT
$1.38B
$2.06M 0.26%
2,498,170
– –
GBIO
32
DELISTED
Generation Bio
GBIO
$2.01M 0.25%
51,035
– –
PACB icon
33
Pacific Biosciences
PACB
$404M
$1.87M 0.23%
229,144
– –
KITT icon
34
Nauticus Robotics
KITT
$6.91M
$1.87M 0.23%
193
– –
PRAX icon
35
Praxis Precision Medicines
PRAX
$8.9B
$1.85M 0.23%
51,901
– –
SANA icon
36
Sana Biotechnology
SANA
$977M
$1.85M 0.23%
468,749
– –
AFRM icon
37
Affirm
AFRM
$26.3B
$1.68M 0.21%
173,560
– –
TNYA icon
38
Tenaya Therapeutics
TNYA
$170M
$1.35M 0.17%
673,270
– –
DYN icon
39
Dyne Therapeutics
DYN
$4.89B
$1.24M 0.15%
107,252
– –
XLO icon
40
Xilio Therapeutics
XLO
$59.9M
$1.12M 0.14%
29,719
– –
MCRB icon
41
Seres Therapeutics
MCRB
$48.4M
$738K 0.09%
6,592
– –
PRDS
42
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$676K 0.08%
400,000
– –
DBTX
43
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$674K 0.08%
328,798
– –
IRON icon
44
Disc Medicine
IRON
$3.03B
$497K 0.06%
25,000
+16,667
+200% +$830K
SRZN icon
45
Surrozen
SRZN
$255M
$481K 0.06%
55,123
– –
DNTH icon
46
Dianthus Therapeutics
DNTH
$6.15B
$131K 0.02%
20,788
– –
LAUR icon
47
Laureate Education
LAUR
$5.24B
– –
-101,804
Closed -$1.07M
1
2

Similar funds

DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $1.82B AUM 19.69% 1-Year Est. Return
SI
Standard Investments New York $1.83B AUM 4.12% 1-Year Est. Return
GC
Gobi Capital San Francisco, California $1.8B AUM 7.28% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
KAM
Kensington Asset Management Austin, Texas $1.84B AUM 13.95% 1-Year Est. Return
OQS
Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
BP
BBR Partners New York $1.79B AUM 16.83% 1-Year Est. Return

Harvard Management Company's Q4 2022 Portfolio in Review

As of Q4 2022, Harvard Management Company held 47 positions worth $807M, up 0.36% from $804M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Trading was light in Q4 2022: portfolio turnover was 2.1%. Harvard Management Company opened no new positions and exited 1, leaving the 47-position portfolio largely intact.

By sector, the portfolio is most concentrated in Communication Services at 43% of assets, down from 48% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Harvard Management Company added most to Grab in Q4 2022, an estimated $10.7M increase.
  • Harvard Management Company's biggest Q4 2022 reduction was EQRx, Inc. Common Stock, cutting an estimated $5.55M.
  • Harvard Management Company fully exited Laureate Education in Q4 2022, selling an estimated $1.07M.
  • Harvard Management Company's ten largest holdings make up 81% of its $807M portfolio in Q4 2022.
  • Harvard Management Company opened 0 new positions and closed 1 in Q4 2022.
  • Harvard Management Company's portfolio value rose 0.36% quarter-over-quarter to $807M.

Based on Harvard Management Company's 13F filing for Q4 2022, filed 10 Feb 2023.